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Abstract
Background:  Of the fewer than 100 cases reported within the literature of constitutional
deletions involving the long arm of chromosome 6, only five have been characterized using high-
resolution microarray analysis. Reported 6q deletion patients show a high incidence of mental
retardation, ear anomalies, hypotonia, and postnatal growth retardation.
Results: We report a 16-month-old male presenting with developmental delay and dysmorphic
features who was found by array-based comparative genomic hybridization (aCGH) to have a ~2.16
Mb de novo deletion within chromosome band 6q16.1 that encompasses only two genes. Expression
studies of the mouse homologue of one of the genes, the ephrin receptor 7 gene (EPHA7), have
shown the gene functions during murine embryogenesis to form cortical domains, determine brain
size and shape, and play a role in development of the central nervous system (CNS).
Discussion:  Our results suggest that deletion of EPHA7  plays a role in the neurologic and
dysmorphic features, including developmental delay, hypotonia, and ear malformations, observed
in some 6q deletion patients.
Background
Conventional cytogenetic analyses have identified fewer
than 100 individuals with constitutional deletions within
6q. A review by Hopkin et al. [1] of 57 previously reported
6q deletion cases characterized cytogenetically attempted
to organize phenotype/karyotype correlations into three
phenotypic groups. Deletions within 6q11 to 6q16, desig-
nated Group A, showed a high incidence of hernias,
upslanting palpebral fissures, and thin lips with a lower
frequency of microcephaly, micrognathia, and heart mal-
formations. Group B deletions spanned 6q15-6q25 and
showed increased intrauterine growth retardation, abnor-
mal respiration, hypertelorism, and upper limb malfor-
mations. Group C comprised deletions in 6q25 to 6qter,
which presented with retinal abnormalities, cleft palate,
and genital hypoplasia. Mental retardation was the only
finding common among all cases of 6q deletion. The three
groups also shared ear anomalies, hypotonia, and postna-
tal growth retardation in 90%, 82%, and 68% of cases,
respectively [1].
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Since the Hopkin et al. [1] review, 10 individuals with
deletions encompassing 6q16.1 identified using aCGH
have been reported [2-7]. Features seen among these cases
are varied as the sizes of these deletions span 6–34 Mb
within 6q. Here, we report an individual with a ~2.1 Mb
deletion within 6q16.1 characterized by high-resolution
oligonucleotide microarray analysis. Within this deletion
is only one known OMIM gene, the ephrin receptor 7
gene, EPHA7. A comparison of the clinical features in the
individual reported here to those of previously reported
individuals suggests that deletion of EPHA7 may play a
role in neurodevelopmental deficits in individuals with
deletions of 6q16.1.
Case presentation
The proband presented at 15 months for genetic evalua-
tion of microcephaly and developmental delay. He was
born to a 21-year-old mother and 22-year-old father at 38
weeks' gestation with birth weight at the 3rd percentile and
length at the 50th percentile. Choroid plexus cysts were
detected prenatally by ultrasound but pregnancy and
labor were uneventful.
At 6–7 months of age, the proband was not sitting and
was noted to have a mild generalized hypotonia. He had
received physical therapy since age 6 months and showed
mild developmental delay in gross motor skills and mul-
tiple other areas. The child was physically small with
microcephaly and short stature. At age 10 months, brain
MRI showed questionable delayed myelination but upon
a second opinion was found to be normal.
Physical examination at 12 months of age showed height
at 70.4 cm (2nd percentile), weight at 7.6 kg (<3rd percen-
tile), head circumference 43.3 cm (1st percentile).
At 15 months of age physical examination showed his
height to be at 74.1 cm (3rd percentile; -1.8 SD), weight at
8.06 kg (<3rd percentile; -3.1 SD), and head circumference
at 44 cm (<3rd percentile; -2.6 SD). In addition to the short
stature, he had generalized hypotonia, mild ptosis, peri-
auricular tags, and cupped ears (Figure 1) with an appar-
ently static encephalopathy. Even though he had a low
weight he did not look malnourished, and his head shape
was normal. It is noted that the mother is about 1.58 m
tall with a head circumference within the 5th–10th percen-
tile for a normal female adult.
A second brain MRI at 15 months indicated mild general-
ized brain atrophy and a focal leukomalacia in the periv-
entricular region of the left occipital lobe which likely
represents an old hemorrhage (arrows) (Figure 2A). In
addition, there was indication of a mild thinning of the
corpus callosum posteriorly (Figure 2B) and a bilateral
decrease in white matter volume of posterior cerebral
hemispheres (Figure 2C).
Karyotype analysis at the 550-band level was normal. Met-
abolic workup, renal studies, and echocardiogram were
essentially normal.
Microarray results
Oligonucleotide aCGH performed on DNA from the
proband's peripheral blood identified a copy-number loss
of 30 oligo probes spanning ~2.16 Mb at 6q16.1
(chr6:92,836,995–94,905,920). The nearest distal oligo-
nucleotide probe on chromosome 6 that was not deleted
was ~83.3 kb away from the deleted region, and the near-
est proximal oligonucleotide probe that was not deleted
was ~56.4 kb away from the deleted region; there are no
genes within either gap (Figure 3A). Fluorescence in situ
hybridization (FISH) using BAC clone RP11-270O11
which encompasses EPHA7 confirmed the deletion (Fig-
ure 3B). FlSH analysis was performed on both parents and
neither parent was found to carry a deletion or transloca-
tion of the 6q16.1 region; thus, the proband's deletion is
apparently de novo in origin.
Discussion
We report a 15-month-old male with a ~2.16 Mb intersti-
tial deletion of 6q16.1 characterized by high-resolution
oligonucleotide microarray. Clinical features include
developmental delay, microcephaly, short stature, con-
genital hypotonia, mild ptosis, periauricular tags, cupped
Proband at age 15 months Figure 1
Proband at age 15 months. Note triangular-shaped face, 
mild ptosis on the left side, and cupped, posteriorly rotated 
ears.Molecular Cytogenetics 2009, 2:17 http://www.molecularcytogenetics.org/content/2/1/17
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ears, and abnormal brain MRI. A comparison of the clini-
cal features observed in our patient and the previously
reported cases identified by aCGH that clearly overlap the
current case shows several common features including
developmental delay (4/4), microcephaly (2/4), mal-
formed ears (4/4), microretrognathia (3/4), and hypoto-
nia (4/4) (Table 1). Hopkin et al. [1] found that the
typical facial features of patients with deletion break-
points within 6q15-6q25 (Group B) included prominent
forehead, microcephaly, microretrognathia, short palpe-
bral fissures, and prominent nose.
The deletion identified in our case encompasses two
genes. One gene, TSG1, a predicted tumor suppressor
gene [8], is not a likely candidate for the clinical features
in our patient. The remaining gene, ephrin receptor 7
(EPHA7) (chr6:94,006,458–94,186,021, UCSC build
March 2006 – hg18) is part of the Eph/ephrin family of
receptor tyrosine kinases (RTK), cell-surface-bound pro-
teins whose signaling mediates cell-to-cell communica-
tion during development and directs the migration and
positioning of cells within many tissue types [9]. The com-
plexity of Eph/ephrin signaling is demonstrated by the
proteins' involvement in bidirectional signaling, partici-
pation in a broad spectrum of developmental processes,
and as a player in other communicative pathways [10].
Murine studies have shown EphA7  functions during
embryogenesis to form cortical domains, determine brain
size and shape, and play a role in development of the CNS
[8-10].
Of the five previously reported 6q deletions detected by
aCGH, three are presumed to encompass EPHA7. Patient
3 reported by Klein et al. [2] and individuals reported by
Le Caignec et al. [4] and Zherebstov et al. [3] had deletions
identified by aCGH with clones covering the 6q16.1
region (Figure 4). Common features among these cases
and the current case include developmental delay, ear
anomalies, and hypotonia (Table 1). Patients 1 and 2
reported by Klein et al. [2] had deletions ranging from 6–
16.4 Mb. However, it is not known whether EPHA7 is
deleted in these two cases because the gene lies between
the most proximal BAC probe known to be deleted and
the next-nearest probe, which is retained, whereas the
deletion observed in Klein et al. [2] patient 3 had a proxi-
mal breakpoint that lies within band q15 (Figure 4) and
thus encompasses EPHA7. In addition, the deletions seen
in the other cases characterized by aCGH are much larger
and thus include many more genes. Although the exact
breakpoints of these previously reported large deletions
cases are unknown, the deletion of only one known gene
in our patient and the presence of clinical features, includ-
ing hypotonia, abnormal or low-set ears, and develop-
mental delay, that are similar to those of the individuals
reported by Klein et al. [2], suggest EPHA7 plays a role in
central nervous system function.
This current case is the smallest deletion encompassing
6q16 reported, to the best of our knowledge, within the
literature to date. Phenotypic overlap between previously
reported 6q16 deletion cases that have been characterized
at the molecular level by array CGH with this case indi-
cates that in humans EPHA7 plays a role in neurological
and dysmorphic features such as developmental delay,
hypotonia, and ear malformations. The characterization
of additional cases at the molecular level will assist with
accurate genotype/phenotype correlations and allow for
the identification of additional features associated with
6q16 deletions.
Brain MRI showing (A) possible brain atrophy and possible hemorrhage, (B) slight thinning of the corpus collosum posteriorly  and (C) decrease in white matter volume seen posteriorly in the cerebral hemispheres bilaterally Figure 2
Brain MRI showing (A) possible brain atrophy and possible hemorrhage, (B) slight thinning of the corpus collo-
sum posteriorly and (C) decrease in white matter volume seen posteriorly in the cerebral hemispheres bilat-
erally.Molecular Cytogenetics 2009, 2:17 http://www.molecularcytogenetics.org/content/2/1/17
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Materials and methods
Oligonucleotide aCGH
Oligonucleotide-based microarray analysis was per-
formed using a 105K-feature whole-genome microarray
(SignatureChip Oligo Solution®, made for Signature
Genomic Laboratories by Agilent Technologies) with one
probe every 10 kb in targeted regions – microdeletion/
microduplication syndromes, the pericentromeric
regions, subtelomeres and genes in important develop-
mental pathways – and an average probe spacing of one
probe every 35 kb throughout the rest of the genome. Two
oligonucleotide probes cover the EPHA7  gene which
spans ~178 kb. Genomic DNA was labeled with Alexa
Fluor dyes 555 or 647 using a BioPrime Total DNA labe-
ling kit (Invitrogen Corp, Carlsbad, CA). Array hybridiza-
tion and washing were performed as specified by the
manufacturer (Agilent Technologies). Arrays were
scanned using an Axon 4000B scanner (Molecular
Devices, Sunnyvale, CA) and analyzed using Agilent Fea-
ture Extraction software v9.5.1 and Agilent CGH Analytics
software v3.5.14. Results were then displayed using cus-
tom oligonucleotide aCGH analysis software (Oli-
goglyphix™; Signature Genomic Laboratories).
FISH Analysis
The deletion was confirmed and visualized by metaphase
fluorescence in situ hybridization (FISH) using a bacterial
artificial chromosome (BAC), clone RP11-270O11, which
encompasses the EPHA7 locus. Metaphase chromosomes
were obtained from the proband's sample by using stand-
ard culturing procedures, and fixed cell suspensions were
dropped onto clean microscope slides. After a 10 min 2×
SSC soak the slides were dehydrated in a series of ethanol
washes (70%, 90%, and 95%) for 2 min each wash. The
slides were then air-dried. The chromosomes were dena-
tured in a 70% formamide, 2 × SSC solution at 70°C for
2 min, immediately placed in 70% ethanol at -20°C for 2
min, then transferred to 80%, 90%, and 100% ethanol at
Analysis of deletion encompassing EPHA7 on 6q16.1 Figure 3
Analysis of deletion encompassing EPHA7 on 6q16.1. (A) Oligonucleotide microarray plot showing a copy-number loss 
of 30 oligo probes spanning 2.16 Mb at 6q16.1 (chr6:92,836,995–94,905,920). Probes are ordered on the x-axis according to 
physical mapping positions with distal 6p to the left and distal 6q to the right. (B) FISH demonstrating deletion of EPHA7. BAC 
clone RP11-270O11 which encompasses EPHA7 was labeled in red and the centromere probe to chromosome 6 (D6Z1) was 
labeled in green as a control. One red signal was present, indicating deletion of EPHA7.
A.
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-20°C for 2 min each, and then air-dried. DNA was
labeled by nick translation (Abbott Molecular Inc., Des
Plaines, IL, USA) with Enzo Red-dUTP or Enzo Green-
dUTP (Abbott). Each was diluted in a 50% formamide
hybridization solution. The double stranded DNA probes
were denatured at 70°C for 10 min and were applied to
the prepared slides. Slides were placed in a moist chamber
and incubated overnight at 37°C. The slides were washed
at 43°C in 0.4× SSC/0.3% Tween solution for 2 min,
placed in 2× SSC/0.1% Tween for 1 min. The slides were
counterstained with DAPI. Cells were examined with a
Zeiss Axioplan II, Imager.M1, or Imager.Z1 fluorescence
microscope equipped with a triple-bandpass filter that
allows multiple colors to be visualized simultaneously.
Digital images were captured and stored with Isis software
V 3.4.0 (Metasystems, Altlussheim, Germany).
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Table 1: Summary of clinical features of individuals with 6q16.1 deletions encompassing EPHA7 characterized by aCGH
Klein et al[2] Patient 3 Le Caignec et al[4] Zherebstov et al[3] Current Case
Sex Male Female Female Male
Array Results
Array type BAC BAC Oligo Oligo
Deletion size 11.3–15.7 Mb 12.9–15.7 Mb 34 Mb 2.1 Mb
Breakpoints q15-q21 q15-q21 q16.1-q22.23 q16.1-q16.1
Birth Measurements
Gestational age Not Reported 40 weeks 39 weeks 38 weeks
Weight 90% 5% -3.8 SD 3rd percentile
Length 90% 25–50% 50% 50th percentile
HC NA NA -3 SD NA
Current Growth 
Parameters
Age 13 years 32 months 7 months 15 months
Weight NA 50% 10th percentile -3.1 SD
Height NA 25–50% -2 SD -1.8 SD
HC >95th percentile 50th percentile 10th percentile <3rd percentile
Neurological Features
Head MRI results Normal Normal CT: subdural hemorrhage due 
to significant brain atrophy
Questionable brain atrophy/
Questionable hemorrhage
Ptosis NA NA NA Mild on left
Eye/Vision anomalies Myopia Strabismus/hypermetropia Poor visual motor 
development
NA
Developmental delay Present Present Present Present
Microcephaly Absent Absent Present (-3 SD) Present (-2 SD)
Head control Head tremor
Face shape Bitemporal narrowing Not reported Flat occiput/heart-shaped face Triangular-shaped face
Dysmorphic Features
Interpupillary distance Hyperteloric Hyperteloric Hyperteloric Normal
Epicanthal folds Present NA Absent Absent
Downslanting palpebral 
fissures
Absent Absent Present Absent
Malformed ears Low-set Upturned, angulated Low-set/posteriorly rotated 
with hypoplastic helices
Cupped ears, periauricular 
tags
Microretrognathia Present Present Present Absent
Organ Malformation
Renal/genitourinary 
anomalies
Post-urethral valve NA Bilateral echogenic kidneys/
pelvicaliectasis of the right 
kidney
Normal
Cardiac anomalies Normal NA Tetrology of Fallot Normal
Hypotonia Present Present Present Present
HC: head circumference; NA: not available; SD: standard deviationPublish with BioMed Central    and   every 
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Zoomed view of 6q15-6q21 Figure 4
Zoomed view of 6q15-6q21. Blue bars represent minimal deletion sizes; black lines represent maximum deletion sizes for 
each patient based on gaps in microarray coverage. Bar A is the current case with a deletion size of 2.1 Mb. Bar B is Klein et al. 
[2] patient 2 with a deletion size of 6–16.2 Mb; Bar C is Klein et al. [2] patient 1 with deletion of size 8.8–16.4 Mb; Bar D is 
Klein et al. [2] patient 3 with deletion size of 11.3–15.7 Mb; Bar E is the patient presented by Le Caignec et al. [4] with deletion 
size of 12.9–15.7 Mb; Bar F is the patient presented by Zherebstov et al. [3] with deletion size of 34 Mb (the bar image for this 
deletion extends beyond the coordinates depicted). The dark blue band represents EPHA7.